Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | CPA1 | P15085 | 2/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1514663 | 0.97 | MDM4 (0.52) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL29370428 | 0.97 | MDM4 (0.52) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL29410226 | 0.97 | MDM4 (0.52) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL799706 | 0.97 | MDM4 (0.52) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL29400401 | 0.97 | MDM4 (0.52) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL3736523 | 0.97 | MDM4 (0.52) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL29385767 | 0.97 | MDM4 (0.52) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL29406248 | 0.97 | MDM4 (0.52) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL8248794 | 0.91 | MDM4 (0.49) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL30927131 | 0.88 | MDM4 (0.49) | MDM4TP53PTPN1MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472272-B2 | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-11-18 | — | — | US | disclosed |
| US-20230348535-A1 | RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-11-02 | — | — | US | disclosed |
| US-20220233726-A1 | NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348535-A1 | RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | FOLH1, KLK3, PSMA3 | MDM4 2848/4885TP53 178/4885PTPN1 4612/4885 |
| US-12472272-B2 | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer | KLK3, FOLH1, HRH3 | MDM4 4202/4885TP53 825/4885PTPN1 2613/4885 |
| US-20220233726-A1 | NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | KLK3, FOLH1, HRH3 | MDM4 4179/4885TP53 910/4885PTPN1 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.